Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2 was written by Jeselsohn, Rinath;Schiff, Rachel;Grinshpun, Albert. And the article was included in Cancer Cell in 2021.Synthetic Route of C23H30N8O This article mentions the following:
Overcoming resistance to CDK4/6 inhibitors is a major clin. challenge. In this issue of Cancer Cell, Freeman-Cook et al. study mechanisms of resistance to CDK4/6 inhibitors by employing a CRISPRa screen. They identify the cyclin E-CDK2 axis and Myc signaling as key pathways of resistance and develop PF-06873600, a selective CDK2/4/6 inhibitor. In the experiment, the researchers used many compounds, for example, 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (cas: 1211441-98-3Synthetic Route of C23H30N8O).
7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (cas: 1211441-98-3) belongs to piperazine derivatives. Piperazine belongs to the family of medicines called anthelmintics. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. Synthetic Route of C23H30N8O
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics